ENTX News and Press, Entera Bio Ltd. From 06/07/23

JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi’s Global...

2023-05-08 14:25:22 ET Amgen ( AMGN ) and Israeli biopharma Entera Bio ( NASDAQ: ENTX ) are ending a research collaboration that began in 2018 that was examining the latter's delivery technology for pre-clinical studies. In a May 5 news release, Entera ( ENTX ) said th...

2023-05-05 16:21:29 ET Entera Bio press release ( NASDAQ: ENTX ): Q1 GAAP EPS of -$0.08 beats by $0.04 . As of March 31, 2023, Entera had cash and cash equivalents of $10.7 million. Entera expects that its existing cash resources are sufficient to meet its projecte...

JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the first quarter ended...

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that its pre-clinical manuscript entitled “Oral Delivery Tec...

JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecol...

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced feedback from its Type D Meeting with the U.S. Food and Drug Admi...

2023-04-03 00:51:45 ET Entera Bio press release ( NASDAQ: ENTX ): FY GAAP EPS of -$0.45. As of December 31, 2022, Entera had cash and cash equivalents of $12.3 million. For further details see: Entera Bio GAAP EPS of -$0.45

JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced a summary of 2022 corporate achievements and financial results f...

2023-03-23 10:17:23 ET The NASDAQ Stock Market notified Entera Bio ( NASDAQ: ENTX ) that it has regained compliance with the minimum bid price requirement. In November 2022, the company was notified that its shares had failed to maintain a minimum bid price of $1 in p...